191 related articles for article (PubMed ID: 25488707)
1. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?
Claxton K; Sculpher M; Palmer S; Culyer AJ
Health Econ; 2015 Jan; 24(1):1-7. PubMed ID: 25488707
[TBL] [Abstract][Full Text] [Related]
2. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
Claxton K; Martin S; Soares M; Rice N; Spackman E; Hinde S; Devlin N; Smith PC; Sculpher M
Health Technol Assess; 2015 Feb; 19(14):1-503, v-vi. PubMed ID: 25692211
[TBL] [Abstract][Full Text] [Related]
3. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
[TBL] [Abstract][Full Text] [Related]
4. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.
Birch S; Gafni A
Health Econ; 2002 Apr; 11(3):185-91. PubMed ID: 11921316
[No Abstract] [Full Text] [Related]
5. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?
Walley T
CNS Drugs; 2004; 18(1):1-12. PubMed ID: 14731055
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
Chen G; Peirce V; Marsh W
Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773
[TBL] [Abstract][Full Text] [Related]
7. Differences in cancer drug assessment between Spain and the United Kingdom.
Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
[TBL] [Abstract][Full Text] [Related]
8. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
9. The NICE cost-effectiveness threshold: what it is and what that means.
McCabe C; Claxton K; Culyer AJ
Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
[TBL] [Abstract][Full Text] [Related]
10. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
11. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal.
Morton A; Adler AI; Bell D; Briggs A; Brouwer W; Claxton K; Craig N; Fischer A; McGregor P; van Baal P
Health Econ; 2016 Aug; 25(8):933-8. PubMed ID: 27374115
[TBL] [Abstract][Full Text] [Related]
12. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
Barbieri M; Hawkins N; Sculpher M
Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
[TBL] [Abstract][Full Text] [Related]
13. The role of NICE technology appraisal in NHS rationing.
Walker S; Palmer S; Sculpher M
Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
[TBL] [Abstract][Full Text] [Related]
14. Searching for a threshold - Not so NICE..
Mooney G; Coast J; Jan S; ; Ryan M; Wiseman V
J Health Serv Res Policy; 2007 Jul; 12(3):190; author reply 190-1. PubMed ID: 17716427
[No Abstract] [Full Text] [Related]
15. Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT.
Clarkson JE; Pitts NB; Goulao B; Boyers D; Ramsay CR; Floate R; Braid HJ; Fee PA; Ord FS; Worthington HV; van der Pol M; Young L; Freeman R; Gouick J; Humphris GM; Mitchell FE; McDonald AM; Norrie JD; Sim K; Douglas G; Ricketts D
Health Technol Assess; 2020 Nov; 24(60):1-138. PubMed ID: 33215986
[TBL] [Abstract][Full Text] [Related]
16. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
17. Prioritizing health technologies in a Primary Care Trust.
Wilson E; Sussex J; Macleod C; Fordham R
J Health Serv Res Policy; 2007 Apr; 12(2):80-5. PubMed ID: 17407656
[TBL] [Abstract][Full Text] [Related]
18. Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA.
Goldman D; Lakdawalla D; Philipson TJ; Yin W
Health Econ; 2010 Oct; 19(10):1109-16. PubMed ID: 20842680
[No Abstract] [Full Text] [Related]
19. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
Hashem F; Calnan MW; Brown PR
Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Assessment Reviews: is cost-effectiveness analysis helpful or necessary?
Mistry H; Mason J
J Health Serv Res Policy; 2018 Oct; 23(4):222-242. PubMed ID: 30309266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
